Howard Levy
Chief Medical Officer
Howard Levy joined Ferghana in 2025 as an advisor and Chief Medical Officer to provide the firm and its potential and current clients with his expertise in clinical development.
Howard is a consultant CMO at BioAegis Tx (recombinant human plasma Gelsolin for ARDS). Prior to that Dr. Levy was CMO at Catalyst Bioscience (hemophilia and complement-related diseases). He was Chairman of the Safety Management Committee at Vergent, and advisor at ZZ Biotech for its Activated Protein C program and Hillhurst Biopharmaceuticals for its carbon monoxide agent in sickle cell disease. He also worked at CSL Behring as Senior Global Program Director for Factor VIII, CMO at Inspiration Biopharmaceuticals and Sangart. Earlier in his career, Dr. Levy was an AVP at Novo Nordisk for Clinical, Medical and Regulatory affairs and at Eli Lilly as Medical Director for acute care.
Dr. Levy has multiple degrees from Witwatersrand University: B.Sc., M.B. B.Ch. and Ph.D in addition to a Master of Medical Management from Carnegie-Melon. He practiced Intensive Care and Pulmonology in South Africa and at the University of New Mexico for several years.
